Dernières nouvelles pour Kazia Therapeutics (NASDAQ:KZIA) Stock

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

<a href="https://www.bloomberg.com/news/articles/2025-06-13/trump-urged-ergen-carr-to-cut-a-deal-on-echostar-spectrum?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-13/trump-urged-ergen-carr-to-cut-a-deal-on-echostar-spectrum?embedded-checkout=true</a>

News

General

SATS

'Trump Urged Ergen, Carr to Cut a Deal on EchoStar Spectrum'- Bloomberg

For all the talk of million-dollar retirements, hitting that seven-figure milestone is a lot rarer than most people assume. In fact, most people won't even come close.
According to the <a href="https://www.federalreserve.gov/econres/notes/feds-notes/greater-wealth-greater-uncertainty-changes-in-racial-inequality-in-the-survey-of-consumer-finances-20231018.html">Federal Reserve's latest Survey of Consumer Finances</a>, just 4.7% of households with retirement accounts have $1 million or more stashed away. And if you're talking about $2 million? That number drops to 1.8%. By the time you hit $3 million, we're in unicorn territory—only <a href="https://www.benzinga.com/personal-finance/24/05/38793057/can-you-guess-how-many-retire-with-a-5-million-nest-egg">0.8% of retirement savers</a> have that much.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
So how <a href="https://www.benzinga.com/personal-finance/24/09/41075540/is-your-401-k-balance-above-average-find-out-if-youre-beating-most-savers">much do most people actually have</a>? Among households led by someone between 65 and 74, the average retirement savings is around $609,230. Sounds decent, until you realize the median is only $200,000, meaning half of households have even less than that. For those over 75, the numbers drop further: $462,410 on average, and a median of just $130,000.
The gap between average and median is a flashing red light. A few super-savers are skewing the curve, while the majority fall short—sometimes dangerously short—of what financial advisors recommend. And this isn't about luxury retirements with yachts and infinity pools. This is about affording groceries, property taxes, and health care when you're no longer working.
Part of the issue is access. Nearly half of all households don't even have a retirement account, according to the Federal Reserve. Whether due to low wages, job instability, or a lack of financial education, many people simply never get started—or start too late.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
And even if they do save, how much income does that actually generate?
On average, retired households bring in just under $28,000 per year, according to data from the <a href="https://www.census.gov/programs-surveys/acs.html">American Community Survey</a>. But that figure shifts depending on where you live. In Alaska, retirees average over $36,000 annually, while in Indiana, it's closer to $20,600. Some states, like California and Florida, fall somewhere in between. And the highest retirement income in the country? That belongs to Washington, D.C., with averages topping $43,000.
Of course, averages only tell part of the story. Incomes are often pieced together from a mix of sources. The vast majority of retirees—<a href="https://www.federalreserve.gov/publications/2023-economic-well-being-of-us-households-in-2022-retirement-investments.htm">over 90%—receive Social Security</a>, and for two-thirds, it makes up more than half of their total income. For about one in four, it's their only income. Pensions, if you're lucky enough to have one, come next. Investment income, rental property, and part-time work make up the rest—but not everyone has access to those streams.
So, is $1 million the magic number? Not exactly. Some experts, like Suze Orman, have famously warned that even <a href="https://www.benzinga.com/personal-finance/management/25/06/45818495/suze-orman-says-retiring-early-is-the-biggest-financial-mistake-youll-ever-make-you-might-need-10-millionjust-so-youll-be-fine">$5 million to $10 million might not be enough</a> for a truly "safe" retirement, depending on your lifestyle and inflation. But others argue you can retire comfortably on much less—especially if your home is paid off, you live modestly, and you don't have high medical costs.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
The bottom line: there's no single number that guarantees peace of mind. But the data makes one thing clear—if you're aiming for that seven-figure milestone, you're part of a very small club.
If you're not there yet, don't panic. Instead, focus on consistency. Even small contributions add up over time, especially with compound growth and smart investing. Consider <a href="https://www.benzinga.com/money/are-you-rich">speaking with a financial advisor</a> who can help you create a plan tailored to your income, goals, and timeline.
Retirement might not come with a trophy, but if you can sleep at night knowing your bills are covered and your future is on track—well, that might just be worth more than the million.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to <a href="https://www.benzinga.com/money/mode-mobile-2">grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Can You Guess How Many People Retire With $1 Million Saved? Hint: Way Fewer Than You Think

Management

VRAX

Virax Biolabs Group CFO Jason Davis To Resign Effective As Of June 13, 2025

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 17.21% on an annualized basis producing an average annual return of 25.49%. Currently, Intuitive Surgical has a market capitalization of $183.57 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 20 years ago, it would be worth $91,843.40 today based on a price of $512.18 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749846617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ISRG

Here's How Much You Would Have Made Owning Intuitive Surgical Stock In The Last 20 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 40.45% at $11.91</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 33.78% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 12.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 11.11% at $0.001</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 10.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 9.26% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 8.96% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 7.94% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 5.56% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 5.17% at $0.55</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 3.62% at $0.04</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 50.00% at $0.0004</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 34.74% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 18.52% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 11.83% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/BGRDF">Tony G Co-Investment</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BGRDF#OTC">BGRDF</a>) shares closed down 8.53% at $3.11</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 7.32% at $1.14</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 5.00% at $0.31</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 4.45% at $1.07</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.44% at $1.29</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 4.26% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 4.17% at $0.79</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed down 4.06% at $61.15</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.71% at $8.83</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed down 3.60% at $12.04</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BGRDF

CLSH

CNBX

CNTMF

CRBP

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CVSI

CWBHF

FFNTF

GNLN

GRWG

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

RMHB

SNDL

SOLCF

TGIFF

UGRO

ZDPY

Cannabis Stock Gainers And Losers From June 13, 2025

Offerings

UUUU

Energy Fuels  Files For Offering Of Up To $300M Common Shares

GDTC

CytoMed Therapeutics Files For Mixed Shelf Of Up To $50M

The legality of hemp is a matter of margins. The Farm Bill legalized hemp-derived cannabinoids in 2018 as long as the plant remained below a threshold of 0.3% Delta-9 THC by dry weight. Cannabis cousin compounds – CBD, THCA, Delta-8 THC, and a slew of minor cannabinoids – were therefore legal provided they met this concentration for Delta-9. The floodgates opened and cannabis products were now available from gas stations to doorstep delivery.
But this rule isn't set in stone. The Farm Bill is meant to be updated every five years and, following two year-long delays, is scheduled for debate and passage this year. This time, senators are fighting back, particularly against psychoactive cannabinoids they view as a loophole in need of closing. 
Early indications suggest lawmakers will push for a total THC standard of 0.3%, potentially curbing access to minor cannabinoids and undoing the scientific, social, and production progress made in this space. Let's take a deeper look at how tenths of a percent will define and ultimately decide the future of legal hemp.
The threshold debate cuts both ways
Last year's postponed draft bill offered the first indication lawmakers wanted to shift from a 0.3% Delta-9 THC standard to a 0.3% total THC standard, encompassing THCA and other THC variants. While this wouldn't likely affect non-THC cannabinoids like CBD, it would target psychoactive cannabinoids.
Ironically, this more restrictive proposal came as other lawmakers argued in the opposite direction. Republican Senator Rand Paul believes the dry weight concentration is too low – and should be tripled – since current rules require testing the flower rather than the final product. This can easily lead to "hot" crops above 0.3%, a real problem with the USDA estimating <a href="https://www.govinfo.gov/content/pkg/FR-2019-10-31/pdf/2019-23749.pdf">about 20% of hemp grown</a> during the crop year exceeds legal THC limits.
Up or down, senators aren't happy with the THC threshold status quo and particularly the newfound legality of psychoactive cannabinoids. This has been a sticking point for conservative lawmakers who feel "duped" that they didn't intend to legalize intoxicating cannabinoids with hemp. As a result, more than 20 states have active bans against cannabinoids like Delta-8, creating a patchwork of production and consumer rules across the country.
A spectrum of cannabinoids
It's worth reiterating that not all cannabinoids are equal. There's an entire world of <a href="https://vitalitycbd.com/what-are-cannabinoids/">more than 120 minor cannabinoids</a> in the hemp plant, with the spectrum ranging from non-psychoactive compounds with solely wellness applications, such as CBD, to psychoactive compounds primarily intended for recreational use, like THCA. And we're only scratching the surface.
The Farm Bill removed red tape and finally let researchers dig into the plant's potential. Early results are promising with CBD proving anecdotal benefits under lab conditions for things like anxiety, inflammation, and sleep. Meanwhile, research into other minor cannabinoids (psychoactive and non-psychoactive) suggests therapeutic applications for conditions such as neuropathic pain, neurodegenerative diseases, skin disorders, and even cancer.
This is important to mention because a total concentration standard could shut the door on some minor cannabinoids and stop this progress in its tracks.&nbsp;
Industry and consumers need clarity
Unfortunately, industry stakeholders will need to wait and see what's next. Congress is getting good at kicking the cannabinoid can down the road, and it seems their legislative agenda is currently focused on the budget. <a href="https://www.agweb.com/news/policy/ag-economy/59-ag-economists-think-congress-wont-pass-new-farm-bill-until-2026">About 60%</a> of agricultural economists believe the Farm Bill – yet again – will go on hold until 2026 due to shifting government priorities.
Regardless of timing, this debate will continue to rage on. And, at the heart of the matter, is how we test products for consumption. I agree that the threshold should be measured against final products rather than raw flower, and producers shouldn't be penalized when concentration factors are often beyond their control. In this regard, there's merit to raising the limit to 1% and only testing the final formulation.
However, it's harder to see the benefit of eliminating psychoactive cannabinoids through a blanket total threshold. From my perspective, as well as that of many in the industry, better production standards and stricter compliance could achieve the same consumer protection goals without further complicating the dry weight framework.
Don't get me wrong – this sector isn't perfect. Some bad actors cut corners on testing and quality, and those of us committed to best practices like organic production, third-party lab verification, and proper labeling welcome rules that raise the bar for consumers. However, a total THC threshold feels like a one-size-fits-all approach that merely seeks to penalize psychoactive cannabinoids. Further, it doesn't address the quality control vacuum left by federal inaction.
Let's hope in the remaining months (or years) of bill debate that industry and lawmakers can come together in good faith to find a solution that works for all sides – one that protects consumers while preserving the promising research and business development we've seen since 2018. Those tenths of a percent may seem insignificant but the stakes couldn't be higher.

Regulations

Opinion

Tenths Of A Percent Will Decide The Future Of Legal Hemp

Rapid7 Appoints Marc Brown As Chairman Of The Board; Corey Thomas To Continue As CEO And Board Member

On June 12, 2025, FibroGen ("FibroGen" or the "Company") entered into a Termination, Asset Transfer and License Agreement (the "Agreement") with HiFiBiO Inc. ("HiFiBiO"). The Agreement terminates the Exclusive License and Option Agreement between the parties, dated June 16, 2021, as amended on February 14, 2024 (the "License Agreement"), and all rights and obligations of FibroGen under the License Agreement shall cease and terminate, subject to certain survival terms.
Under the Agreement, FibroGen has also licensed HiFiBiO the anti-CCR8 and anti-Gal-9 intellectual property developed by FibroGen. In the event HiFiBiO sublicenses Gal-9 (FG-3165) and/or CCR8 (FG-3175) assets, FibroGen is eligible to receive a mid single-digit to low double-digit share of HiFiBiO's license revenues and low double-digit share of HiFiBiO's commercial royalties. In the case HiFiBiO commercializes either asset, FibroGen has the potential to receive single digit royalties based upon worldwide net sales.
﻿

Contracts

FGEN

FibroGen Terminates License Agreement With HiFiBiO, Transfers Anti-CCR8 And Anti-Gal-9 Assets, And Secures Potential Royalties From Future Sublicensing Or Commercialization

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of a Tires Plus property for $1.7 million. The property is located in a highly trafficked corridor in Georgia and corporate-operated under a triple net lease with approximately three years of term remaining. The transaction was priced at a 7.4% cap rate on rent as of the closing date and exclusive of transaction costs.
 &nbsp;

FCPT

Four Corners Property Trust Acquires Tires Plus Property For $1.7M

On June 3, 2025, the United States District Court for the District of Connecticut (the "District Court") issued an order granting preliminary approval of the proposed settlement of the consolidated derivative actions captioned In re the Lovesac Company Derivative Action, Case No. 3:24-cv-01260-VAB (D. Conn.), on the terms set out in the Stipulation of Settlement dated May 19, 2025 ("Stipulation of Settlement" and, with its exhibits, the "Settlement Agreement"). On June 6, 2025, the District Court amended the order granting preliminary approval to adjust certain dates in the prior June 3 order.

Legal

LOVE

Federal Court Grants Preliminary Approval Of Lovesac Derivative Lawsuit Settlement On June 3, 2025

Dow Files For Mixed Shelf; Size Not Disclosed

<a href="https://www.bloomberg.com/news/articles/2025-06-13/google-s-plan-to-buy-security-firm-wiz-gets-antitrust-review">https://www.bloomberg.com/news/articles/2025-06-13/google-s-plan-to-buy-security-firm-wiz-gets-antitrust-review</a>

GOOG

GOOGL

'Google's Plan to Buy Security Firm Wiz Gets Antitrust Review'- Bloomberg

Buybacks

FELE

Franklin Electric Completes 1.2M Shares Purchase At $86.78 Each From Patricia Schaefer Settlement Trust

Johnson Controls International Reveals $9B Increase To Share Repurchase Program

OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) has outperformed the market over the past 20 years by 6.14% on an annualized basis producing an average annual return of 14.43%. Currently, OSI Systems has a market capitalization of $3.86 billion. 
Buying $1000 In OSIS: If an investor had bought $1000 of OSIS stock 20 years ago, it would be worth $14,601.78 today based on a price of $229.54 for OSIS at the time of writing.
<h3>OSI Systems's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749845732_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OSIS

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Carnival Corporation &amp;&nbsp;plc ((NYSE/LSE: CCL, NYSE:<a href="https://www.benzinga.com/stock/CUK#NYSE">CUK</a>) (the "Company") today announced that it has successfully arranged a new $4.5 billion multi-currency revolving credit facility (the "New Revolver"). &nbsp;The New Revolver matures in June 2030 and will replace the existing multi-currency revolving credit facility of Carnival Holdings (Bermuda) II Limited, a subsidiary of Carnival Corporation. The New Revolver also contains an accordion feature, allowing for up to $1.0 billion of additional revolving commitments.

Carnival Corp & Plc Arranges New $4.5B Multi-Currency Revolving Credit Facility

FDA states heavy workload and limited resources prevent meeting PDUFA goal date of June 17
Agency indicates anticipated decision within four weeks
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54276083&amp;newsitemid=20250613608281&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=e86059e83cf65cec245451f3ef33b01b">KalVista Pharmaceuticals</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company's investigational oral on-demand treatment for hereditary angioedema (HAE). The FDA notified the Company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met due to heavy workload and limited resources. The FDA indicated that it expects to deliver a decision within approximately four weeks.
The FDA has not requested additional data or studies and has not raised any concerns regarding the safety, efficacy or approvability of sebetralstat. KalVista has addressed all prior information requests in a timely manner, and the Company believes the only remaining item under FDA review is the finalization of the labelling.

KALV

KalVista Pharma Says FDA Will Not Meet PDUFA Goal Date For New Drug Application For Sebetralstat, Oral On-Demand Treatment For Hereditary Angioedema

The S&amp;P Steel Index is gaining in 2025, buoyed by a combination of tariff leverage, robust balance sheets, and strong returns on capital.
Year to date, the S&amp;P Steel Sub-Industry Index is up 8.40% as of June 12, as the US steel sector stabilizes. It has room to grow over the short term after President Trump's decision to double US steel tariff imports from 25% to 50% as of June 4, 2025, following a new executive order.
But tariffs aren&#8217;t the only reason steel stocks are rising.
The trade policy shift, announced in late May during a rally at a U.S. Steel factory near Pittsburgh, immediately sent steel stocks soaring, with Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) rising 26% in a single day following the announcement, while Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) and Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) saw gains of 10-11%. "The tariffs effectively raise the price floor for steel in the U.S. market by making imported steel significantly more expensive," said Tracy Shuchart, senior economist at NinjaTrader in New York City. "According to market data, benchmark steel prices have already increased from $725 per metric ton before the tariff announcement to $875 per metric ton currently."
It&#8217;s not only tariffs that are supporting steel industry gains.
"Steel's rally is a mix of short-term catalysts and long-term structural forces," said Dan Buckley, chief analyst at DayTrading.com. "US tariffs are boosting expectations for domestic producers, while sustained federal spending on infrastructure and reshoring is aiding durable demand."
"Add in supply chain restocking, auto sector recovery, and disciplined capital returns from top players like Nucor and Steel Dynamics, and the sector is showing a more stable profile," Buckley added.
The tariff portion of that equation may not have a long shelf life, so investors should proceed cautiously. Talks between the U.S. and Mexico are already underway to curb the 50% tariff figure.
"For example, the two countries are exploring a quota system that would allow a specific amount of Mexican steel to enter the U.S. duty-free or at lower rates, with only excess amounts subject to the full 50% levy," Shuchart noted. "This negotiation explains why some steel stocks like Nucor fell 6.1% on June 11, as investors reacted to the possibility of tariff exemptions. The European Union has also strongly opposed the increased tariffs, warning of potential countermeasures."
<h2 class="wp-block-heading">Benzinga Exclusive: Master Trader Reveals ‘Power Patterns' Behind 100% Gains</h2>
For the last decade, these three "Power Patterns" have delivered winning trades during the summer &#8211; one an astonishing 90% of the time. Now they're firing up again over the next 75 days. Want a 30-year veteran trader to show you how to play them? See <a href="https://events2.benzinga.com/power-pattern-profits-live/?utm_campaign=power-pattern-registration&amp;utm_adType=sponsorad&amp;utm_ad=RD061625&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter&amp;el=ResearchDaily">HERE</a> How a Master Trader Plays These "Power Patterns"
Investors should factor in other supportive steel sector impactors also driving industry stocks forward. Shuchart points to infrastructure investment, where ongoing and planned infrastructure projects drive demand for steel products across the United States.
Domestic construction activity is up, too, and in high-growth areas.
"Despite higher interest rates, commercial construction remains relatively robust, supporting demand for structural steel," Shuchart said. "Additionally, key steel-consuming industries like automotive and machinery manufacturing have shown surprising resilience in 2025, and the expansion of renewable energy infrastructure requires significant steel inputs, creating a new demand source for the industry.&#8221;
With a strong tailwind from U.S. government policy and solid fundamentals from the steel sector in place, which steel stocks make the most sense for investors right now? These three steel plays could add a profitable element to your portfolio.
<h2 class="wp-block-heading">Nucor</h2>
Trading at $121 per share and 4.4% over the past month, Charlotte, N.C.-based Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>), a steel products manufacturer, also offers a sturdy 1.82% dividend yield.
"Despite recent volatility due to potential Mexico tariff negotiations, Nucor remains the premier U.S. steel producer with industry-leading margins, a strong balance sheet, and consistent dividend growth," Shuchar said. "Its EAF production model provides cost flexibility, and its diverse product mix offers exposure to multiple end markets."
<h2 class="wp-block-heading">Steel Dynamics</h2>
At $133 per share and with a 1.50% dividend yield, Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) is up a healthy 16.7% year to date. However, the stock (like Nucor) is down moderately this week after the US-Mexico tariff negotiations went public. Wall Street is buzzing over those talks, which could center on reducing or even removing the 50% tariffs to a lower amount based on historical trade volumes.
Yet there's a lot to like about Steel Dynamics, which, like Nucor, offers investors operational efficiency and one of the lowest production cost structures in the industry. "The company has been expanding its value-added product portfolio, which should support margins even if base steel prices moderate," Shuchar said.
<h2 class="wp-block-heading">ArcelorMittal</h2>
Buckley is bullish on the Luxembourg-based ArcelorMittal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>), which engages in steelmaking and mining activity. "MT adds global diversification" to the manufacturing section of an investment portfolio," Buckley said. MT shares are up 30.6% year to date at $30 per share with a 1.55% dividend yield.
MT could also benefit from Nippon Steel's purchase of US Steel. Under an agreement inked in October 2024, ArcelorMittal is set up to purchase Nippon's 50% share in a joint venture deal for $1. In addition, MT will deep-six $1 billion of joint venture shareholder loans in an agreement that JP Morgan analyst Dominic O'Kane called a "major positive" for ArcelorMittal.
<h2 class="wp-block-heading">Look for Solid Fundamentals with Steel Stocks</h2>
Don't hit any "buy" buttons on steel stocks until you grasp a company's underlying fundamentals, even if the tariff wars seem to be working out in your favor.
Buckley said investors should prioritize key factors with steel companies. In his view, the best steel investments combine:
<ul class="wp-block-list">
<li>Cost-efficient production.</li>
<li>Strong returns on capital.</li>
<li>Strong balance sheets (i.e., low net debt, high-interest coverage, ample cash reserves, stable working capital, prudent capital expenditure discipline).</li>
<li>Quality net margins (i.e., a ~5% net margin is a solid baseline for this sector, and a 7- 10% range is excellent).</li>
</ul>
"Industry companies with high-margin, value-added products and sustainable dividend growth are best, rather than chasing commodity pricing volatility compared to the overall market," Buckley said. "Overall, steel stocks are less about chasing trends and more about aligning with the economic security playbook we're seeing as a geopolitical theme."
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

STLD

3 Steel Stocks To Get You Through The Market's Troubles

Press Releases

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Small Cap

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Peraso Inc. (NASDAQ: PRSO): The Only Pure-Play mmWave Stock Poised for Growth – More Stocks Inside

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil

Kazia Therapeutics Highlights Recent Progress and Provides Business Update

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

Small-Cap Disruptors KZIA, SNYR, HSDT, TRNR, PRSO Lead Momentum – More Microcap Stocks Inside

Comments

Kazia Therapeutics

Actualités

Dernières nouvelles pour Kazia Therapeutics (NASDAQ:KZIA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL